P123 Optimal Regimen of Neoadjuvant Systemic Therapy for HER2 Positive Early Breast Cancer

P123 Optimal Regimen of Neoadjuvant Systemic Therapy for HER2 Positive Early Breast Cancer

Bibliographic Details
Main Authors:	C. Lo, M.-Y. Wang, W.-H. Kuo, Y.-H. Lee, L.-W. Tsai, Y.-S. Lu, C.-H. Lin, D.-Y. Chang, W.-W. Chen, C.-S. Huang
Format:	Article
Language:	English
Published:	Elsevier 2023-03-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977623002400

Similar Items

Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis
by: J. Zhang, et al.
Published: (2021-04-01)

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
by: Li S, et al.
Published: (2018-09-01)

P135 Response to neoadjuvant chemotherapy in HER2-positive breast cancers: a single-centre study
by: K. Ben Hamida, et al.
Published: (2023-03-01)

Neoadjuvant therapy for HER2-positive breast cancer
by: Nikolina Dukić, et al.
Published: (2019-06-01)

Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based Regimens for HER2-positive Locally Advanced Breast Cancer
by: Wei-Hsin Liu, et al.
Published: (2014-09-01)

Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells
by: Shen Y, et al.
Published: (2018-01-01)

Current neoadjuvant treatment options for HER2 positive breast cancer
by: Abdel-Razeq H, et al.
Published: (2011-08-01)

Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen
by: Jiujun Zhu, et al.
Published: (2022-09-01)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
by: Nadia Harbeck
Published: (2022-03-01)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
by: N. Harbeck
Published: (2021-04-01)

Neoadjuvant systemic therapy of HER2-positive breast cancer
by: M A Frolova
Published: (2015-12-01)

Neoadjuvant niraparib in patients with HER2-negative, BRCA-mutated resectable breast cancer
by: L.M. Spring, et al.
Published: (2021-04-01)

Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer
by: Binwei Lin MM, et al.
Published: (2023-11-01)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
by: I.P.C. Buzatto, et al.

Effects of Different Neoadjuvant Chemotherapy Regimens on Immune Indicators and Tumor Microenvironment in HER-2-positive Breast Cancer Patients
by: PEI Bei, CHENG Lin, XU Lingyun
Published: (2023-09-01)

Strategy and Status of Neoadjuvant Therapy for HER2-positive Breast Cancer
by: LIU Yunjiang, et al.
Published: (2024-01-01)

Review of the status of neoadjuvant therapy in HER2-positive breast cancer
by: Gavin P. Dowling, et al.
Published: (2023-01-01)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
by: Han Y, et al.
Published: (2019-05-01)

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
by: M. C. Liefaard, et al.
Published: (2024-04-01)

Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers
by: Christopher Y.C. Chow, et al.
Published: (2022-10-01)

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
by: Emanuela Ferraro, et al.
Published: (2022-03-01)

P112 Clinicopathological factors for predicting tumor response in hormonal positive/HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
by: P. Yincharoen, et al.
Published: (2023-03-01)

P043 Characteristics and clinical outcomes of patients with HER2-low breast cancer
by: S. Koh, et al.
Published: (2023-03-01)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
by: Advani P, et al.
Published: (2015-09-01)

Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis
by: Jie Zhang, et al.
Published: (2021-04-01)

131I-Labeled Anti-HER2 Nanobody for Targeted Radionuclide Therapy of HER2-Positive Breast Cancer
by: Zhao L, et al.
Published: (2023-04-01)

<i>FGFR1</i> Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
by: María Gaibar, et al.
Published: (2022-01-01)

Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer
by: E. V. Lubennikova, et al.
Published: (2021-12-01)

Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer
by: Junyoung Shin, et al.
Published: (2023-02-01)

The efficacy and safety of dual HER2 blockade with a pertuzumab-based regimen for metastatic breast cancer patients previously exposed to an anti-HER2 agent: a systematic review and meta-analysis
by: S. Chen, et al.
Published: (2021-04-01)

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
by: M. C. Liefaard, et al.
Published: (2023-06-01)

The Value of Neoadjuvant Anthracycline-Based Regimens for HER2-Positive Breast Cancer: A Systematic Review and Meta-analysis Including 1366 Patients
by: Yuqin Ding, et al.
Published: (2023-09-01)

Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
by: Zheng-Jun Yang, et al.
Published: (2024-01-01)

Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer
by: Anshul Gupta, et al.
Published: (2023-01-01)

Dynamics of circulating tumor DNA during postoperative radiotherapy for triple-negative breast cancer in patients undergoing neoadjuvant chemotherapy and breast surgery
by: H. Kim, et al.
Published: (2021-04-01)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
by: Alexis LeVee, et al.
Published: (2023-05-01)

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis
by: Wu Y, et al.
Published: (2018-09-01)

Predictors of response to neoadjuvant treatment and changes to HER2 status in HER2-positive invasive breast cancer
by: LIU Jianlan, CHEN Daishi, HU Hong, ZHOU Dongxian, HU Jintao
Published: (2022-05-01)

Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
by: Patrik Pöschke, et al.
Published: (2023-09-01)

The Combined Effect of Nanobubble-IR783-HPPH-Affibody Complex and Laser on HER2-Positive Breast Cancer
by: Cai W, et al.
Published: (2023-01-01)